UPDATED: Pfizer fields a CRL for a $295M rare disease play, giving rival a big head start
Pfizer won’t be adding a new rare disease drug to the franchise club — for now, anyway.
The pharma giant put out word that their FDA application for the growth hormone therapy somatrogon got the regulatory heave-ho, though they didn’t even hint at a reason for the CRL. Following standard operating procedure, Pfizer said in a terse missive that they would be working with regulators on a followup.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.